George Kesarios
Contributor since: 2008
Latest Articles
Ceragon Networks Delivers, But Is A Further Rise In The Stock Justified?
How To Play Groupon After The Fall
scPharmaceuticals: A Speculation Play With A High Margin Of Safety
GoPro: Disappointing Margins Will Continue To Keep Shares Depressed
Micron: My Top Pick For 2019
T2 Biosystems Diagnostic Arsenal Expanded By Leaps And Bounds But No One Noticed
Aptevo Therapeutics: IXINITY Might Prove To Be A Never Expiring Option On The Company's Core Pipeline
Groupon: Waiting For Panic To Sink In
Why Snap Might Go Lower, Much Lower
Greek Banks Continue To Melt Like Butter
4 Worries I Have For 2018 And 2019
Greece: Forget About The Positive Headline News, Nothing Has Changed
$700 Gold Is Possible
Buy The Dip In ExOne, The Market Got It Wrong
Aptevo Therapeutics Continues To Impress
Ceragon Networks: Time For A Breather
GoPro: Fundamentals Continue To Deteriorate
T2 Biosystems Continues To Execute, Slowly But Surely
What You Always Knew About Facebook But Did Not Want To Admit
Why I Sold AMD
Qualcomm And NXP, You Win Either Way
Should You Buy Groupon, Betting On A Buyout?
Gold: Still No Demand, And The Very Long-Term Trend Is Poised For Multi-Year Lows
If You Want To Blame Someone For The U.S. Trade Deficit With China, Blame Apple
AMD's Pillars Of Growth Over The Next Decade
AMD Shorts Keep Pushing, Intelsat Shorts Are In Trouble, ExOne Shorts Are Playing With Fire
BlackBerry: Valuation Continues To Be A Concern
Time To Go Long The ExOne Company
Intelsat Just Pulled A Rabbit Out Of The Hat
T2 Biosystems: Still A Buy After The Rally
AMD: My New 12-Month Forward Price Target Is Now $30 A Share
Organovo Holdings: A Small Biotech At A Great Valuation